US 11,052,147 B2
Stable virus-containing composition
Ahmad Shakeb Sediq, Basel (CH); Wouter Frank Tonnis, Berlin (DE); and Martinus Anne Hobbe Capelle, Sassenheim (NL)
Assigned to JANSSEN VACCINES & PREVENTION B.V.
Appl. No. 16/612,561
Filed by Janssen Vaccines & Prevention B.V., Leiden (NL); and Bavarian Nordic A/S, Kvistgaard (DK)
PCT Filed May 15, 2018, PCT No. PCT/IB2018/053390
§ 371(c)(1), (2) Date Nov. 11, 2019,
PCT Pub. No. WO2018/211419, PCT Pub. Date Nov. 22, 2018.
Claims priority of application No. 17171105 (EP), filed on May 15, 2017; and application No. 17199139 (EP), filed on Oct. 30, 2017.
Prior Publication US 2020/0197512 A1, Jun. 25, 2020
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01); A61K 39/275 (2006.01); A61K 39/285 (2006.01); A61P 31/04 (2006.01); A61K 47/20 (2006.01)
CPC A61K 39/285 (2013.01) [A61K 47/20 (2013.01); A61P 31/04 (2018.01)] 20 Claims
 
1. A composition comprising a) a poxvirus; b) a buffer; and c) a sulfate salt at a concentration between about 5 mM and 300 mM, wherein said composition has a pH of between about 6.0 and 8.5.